Rare cancer trial design: Lessons from FDA approvals

Clinical Cancer Research

Volumn 18, Issue 19, 2012, Pages 5172-5178

  Gaddipati, Himabindu ^a   Liu, Ke ^b   Pariser, Anne ^a   Pazdur, Richard ^b  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b Center for Drug Evaluation and Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GEMTUZUMAB; VANDETANIB;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CANCER INCIDENCE; CANCER PATIENT; CANCER RESEARCH; DRUG APPROVAL; DRUG EFFICACY; DRUG MARKETING; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HUMAN; MALIGNANT NEOPLASTIC DISEASE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; THYROID CANCER; TREATMENT INDICATION;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG APPROVAL; HUMANS; NEOPLASMS; RARE DISEASES; RESEARCH DESIGN; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84866902444     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-1135     Document Type: Article

References (26)

1. Orphan Drug Act. Pub. L. No. 97-414 (1983) (as amended). [cited 2012 May 29]. Available from: http://www.fda.gov/RegulatoryInformation/Legislation/ FederalFoodDrugandCosmeticActFDCAct/SignificantAmendmentstotheFDCAct/ OrphanDrugAct/default.htm.
2. Office of the Law Revision Counsel. U.S. House of Representatives. Designation of drugs for rare diseases or conditions: United States Code. 21 U.S.C. §360bb(a)(2). [cited 2012 May 29]. Available from: http://143.231.180.80/view.xhtml?req=21+U. S.C.+360bb&f=&fq= true&num=0&hl=true.
3. Office of the Law Revision Counsel. U.S. House of Representatives. Protection for drugs for rare diseases or conditions: United States Code. 21 U.S.C. §360cc (a). [cited 2012 May 29]. Available from: http://143.231.180.80/view.xhtml?req=21+U.S.C.+360cc&f=&fq=true&num= 0&hl=true.
4. Food and Drug Administration, 2011. Designating an orphan product: drugs and biologics. [cited 2012 May 29]. Available from: http://www.fda.gov/ ForIndustry/DevelopingProductsforRare DiseasesConditions/ HowtoapplyforOrphanProductDesignation/default.htm.
5. Food and Drug Administration, 2011.Development and approval process (drugs): exceptions to fee requirements. [cited 2012 May 29]. Available from: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/SmallBusinessAssistance/ ucm069943.htm#P112-8652.
6. Pariser AR, Xu K, Milto J, Cote TR. Regulatory considerations for developing drugs for rare diseases: orphan designations and early phase clinical trials. Discov Med 2011;11:367-75.
7. Food and Drug Administration, 2011. FDA Rare Diseases Program. [cited 2012 May 29]. Available from: http://www.fda.gov/ForIndustry/ DevelopingProductsforRareDiseasesConditions/default.htm.
8. Dagher R, Johnson J, Williams G, Keegan P, Pazdur R. Accelerated approval of oncology products: a decade of experience. J Natl Cancer Inst 2004;96:1500-9. (Pubitemid 39445531)
9. Richey EA, Lyons EA, Nebeker JR, Shankaran V, McKoy JM, Luu TH, et al. Accelerated approval of cancer drugs: improved access to therapeutic breakthroughs or early release of unsafe and ineffective drugs? J Clin Oncol 2009;27:4398-405.
10. Food and Drug Administration. Approval based on a surrogate endpoint or on an effect on a clinical endpoint other than survival or irreversible morbidity, 21 C.F.R. Sect. 314.510. [cited 2012 May 29]. Available from: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=314. 510.
11. Food and Drug Administration. Approval based on a surrogate endpoint or on an effect on a clinical endpoint other than survival or irreversible morbidity, 21 C.F.R. Sect. 601.41. [cited 2012 May 29]. Available from: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=601.41.
12. Orphan Drug Regulations: Proposed Rule: 21 CFR Part 316. Food and Drug Administration. Federal Register 2011;76:64868-79.
13. Koivunen JP, Mermel C, Zejnullahu K, Murphy C, Lifshits E, Holmes AJ, et al. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res 2008;14:4275-83.
14. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007;448:561- 6.
15. Summary minutes of the Oncologic Drugs Advisory Committee Meeting 2011 Feb 8. Food and Drug Administration, 2011. Silver Spring, MD. [cited 2012 May 29]. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/ CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/UCM250472.pdf.
16. Gatta G, Capocaccia R, Trama A, Martinez-Garcia C. The burden of rare cancers in Europe. In: DelaPaz MP, Groft SC, editors: Rare disease epidemiology, advances in experimental medicine and biology. Berlin, Germany: Springer; 2010. p. 285-303.
17. Surveillance, Epidemiology and End Results (SEER). Bethesda, MD: National Cancer Institute. [cited 2012 May 29]. Available from: http://seer.cancer.gov/.
18. National Comprehensive Cancer Network (NCCN). Fort Washington, PA: NCCN, [cited 2012 May 23]. Available from: http://www.nccn.org/index.asp.
19. UpToDate. Waltham, MA: UpToDate. [cited 2012 May 29]. Available from: http://www.uptodate.com/index.
20. Food and Drug Administration, 2010. Fast track, accelerated approval and priority review: accelerating availability of new drugs for patients with serious diseases. [cited 2012 May 29]. Available from: http://www.fda.gov/ ForConsumers/ByAudience/ForPatientAdvocates/ SpeedingAccesstoImportantNewTherapies/ucm128291.htm.
21. Food and Drug Administration, 2010. FDA news release. [cited 2012 May 29]. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ ucm216448.htm.
22. Miyamoto BE, Kakkis ED. The potential investment impact of improved access to accelerated approval on the development of treatments for low prevalence rare diseases. Orphanet J Rare Dis 2011;6:49.
23. Kesselheim AS, Myers JA, Avorn J. Characteristics of clinical trials to support approval of orphan vs nonorphan drugs for cancer. JAMA 2011;305:2320-6.
24. Johnson JR, Ning YM, Farrell A, Justice R, Keegan P, Pazdure R. Accelerated approval of oncology products: the Food and Drug Administration experience. J Natl Cancer Inst 2011;103:636-44.
25. New Drugs, 2008. Federal Food, Drug, and Cosmetic Act (FD&C Act), Sect. 505(e). [21 USC x355]. [cited 2012 May 29]. Available from: http://www.fda.gov/RegulatoryInformation/Legislation/ FederalFoodDrugandCosmeticActFDCAct/FDCActChapterVDrugsandDevices/default.htm
26. Guidance for Industry - clinical trial endpoints for the approval of cancer drugs and biologics: Food and Drug Administration, 2007. [cited 2012 May 29]. Available from: http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm071590.pdf.